Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02232425 · ClinicalTrials.gov registry record · Phase 2
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
A Phase 2 study, sponsored by Ixchelsis Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT02232425: Completed Phase 2 study, sponsored by Ixchelsis Limited.
NCT02232425 is a Phase 2 study that has completed, run by Ixchelsis Limited. The registered enrollment target is 88 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02232425, a Phase 2 study, has completed, sponsored by Ixchelsis Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.
Interventions
- DRUG Placebo
- DRUG IX-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02232425
The ClinicalTrials.gov registry entry for NCT02232425 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ixchelsis Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02232425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02232425 about?
NCT02232425 is a clinical study titled "IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)". The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.
What is the current status of trial NCT02232425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2014-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02232425?
The interventions under investigation include: Placebo (DRUG), IX-01 (DRUG).
Who is sponsoring clinical trial NCT02232425?
This trial is sponsored by Ixchelsis Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.